Open-label, dose escalation phase I study in healthy volunteers to evaluate the safety and pharmacokinetics of a human monoclonal antibody to Clostridium difficile toxin A
- 7 May 2008
- Vol. 26 (27-28), 3404-3409
- https://doi.org/10.1016/j.vaccine.2008.04.042
Abstract
No abstract availableKeywords
This publication has 54 references indexed in Scilit:
- Human Monoclonal Antibodies Directed against Toxins A and B Prevent Clostridium difficile -Induced Mortality in HamstersInfection and Immunity, 2006
- Open-Label, Dose Escalation Study of the Safety and Pharmacokinetic Profile of Tefibazumab in Healthy VolunteersAntimicrobial Agents and Chemotherapy, 2005
- Descriptive study of intravenous immunoglobulin for the treatment of recurrent Clostridium difficile diarrhoeaJournal of Antimicrobial Chemotherapy, 2004
- High Frequency of Antibiotic-Associated Diarrhea due to Toxin A-Negative, Toxin B-Positive Clostridium difficile in a Hospital in Japan and Risk Factors for InfectionEuropean Journal of Clinical Microbiology & Infectious Diseases, 2003
- A nonsense mutation abrogates production of a functional enterotoxin A in Clostridium difficile toxinotype VIII strains of serogroups F and XFEMS Microbiology Letters, 1999
- A nonsense mutation abrogates production of a functional enterotoxin A inClostridium difficiletoxinotype VIII strains of serogroups F and XFEMS Microbiology Letters, 1999
- Immune response to Clostridium difficile infectionEuropean Journal of Gastroenterology & Hepatology, 1996
- Neutrophil recruitment in Clostridium difficile toxin A enteritis in the rabbit.Journal of Clinical Investigation, 1994
- Treatment with intravenously administered gamma globulin of chronic relapsing colitis induced by Clostridium difficile toxinThe Journal of Pediatrics, 1991
- Ultrastructural effects of Clostridium difficile toxin B on smooth muscle cells and fibroblastsExperimental Cell Research, 1983